Biogen Angles For Facet With 2nd Hostile Bid

Law360, New York (December 4, 2009, 5:11 PM EST) -- Biogen Idec Inc. has made a “best and final” tender offer to purchase Facet Biotech Corp., upping its ante from $14.50 to $17.50 a share and urging Facet's stockholders to send a signal to their board by selling their stake in the company.

Biogen made its second offer to acquire all outstanding shares of Facet stock in a letter addressed to the company's stockholders from Biogen CEO James Mullen Thursday.

“Over the past three months we have had conversations with certain Facet stockholders which lead us...
To view the full article, register now.